Organogenesis

OverviewSuggest Edit

Organogenesis Inc. is a leading regenerative medicine company with the unique skill set to take complex, living therapies from research and development, through manufacturing, to successful commercialization to reach patients today. As a pioneer in the field of regenerative medicine, Organogenesis received the first FDA approval of a living, allogeneic, cell-based product Apligraf®, approved for the treatment of venous leg ulcers.

TypePrivate
Founded1985
HQCanton, US
Websiteorganogenesis.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Jan 2020)785(-1%)
Job Openings32

Key People/Management at Organogenesis

Gary S. Gillheeney

Gary S. Gillheeney

President and Chief Executive Officer
Timothy M. Cunningham

Timothy M. Cunningham

CFO
Brian Grow

Brian Grow

Chief Commercial Officer
Patrick Bilbo

Patrick Bilbo

COO
Howard Walthall

Howard Walthall

Executive Vice President, Strategy and Market Development
Antonio S. Montecalvo

Antonio S. Montecalvo

Vice President, Health Policy and Contracting
Show more

Organogenesis Office Locations

Organogenesis has offices in Canton, San Diego and Kanton Reinach
Canton, US (HQ)
85 Dan Rd
Canton, US
150 Dan Rd
San Diego, US
10933 N Torrey Pines Rd, La Jolla
Kanton Reinach, CH
Christoph Merian-Ring 11
Show all (4)

Organogenesis Financials and Metrics

Summary Metrics

Founding Date

1985

Organogenesis total Funding

$75 m

Organogenesis latest funding size

$20 m

Time since last funding

3 years ago

Organogenesis investors

Organogenesis's latest funding round in May 2017 was reported to be $20 m. In total, Organogenesis has raised $75 m
Show all financial metrics

Organogenesis Online and Social Media Presence

Embed Graph

Organogenesis News and Updates

Organogenesis Holdings Inc. Reports Preliminary Revenue Results for the Fourth Quarter and Fiscal Year 2019

CANTON, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today rep…

Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock

CANTON, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today ann…

New ReNu® Data from Organogenesis Highlighted at ICRS 2019 World Congress

CANTON, Mass. and VANCOUVER, British Columbia, Oct. 05, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sport…

Organogenesis Holdings Inc. Reports Second Quarter and First Half 2019 Financial Results

CANTON, Mass., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today rep…

Organogenesis Holdings Commences Offer to Exchange Class A Common Stock for any and all Outstanding Public Warrants and Consent Solicitation

CANTON, Mass., July 22, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO) (the “Company,” “we” or “our”) today announced that it has commenced an offer to exchange (“Offer to Exchange”) 0.095 shares of the Company’s Class A common stock (“Class A Common Stock”) for each outstandi…

Organogenesis Joins Russell 2000®, Russell 3000® and Russell Microcap® Indexes

CANTON, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced to…
Show more

Organogenesis Frequently Asked Questions

  • When was Organogenesis founded?

    Organogenesis was founded in 1985.

  • Who are Organogenesis key executives?

    Organogenesis's key executives are Gary S. Gillheeney, Timothy M. Cunningham and Brian Grow.

  • How many employees does Organogenesis have?

    Organogenesis has 785 employees.

  • Who are Organogenesis competitors?

    Competitors of Organogenesis include Arrowhead Pharmaceuticals, Capstone Therapeutics and TetraGenetics.

  • Where is Organogenesis headquarters?

    Organogenesis headquarters is located at 85 Dan Rd, Canton.

  • Where are Organogenesis offices?

    Organogenesis has offices in Canton, San Diego and Kanton Reinach.

  • How many offices does Organogenesis have?

    Organogenesis has 4 offices.